Milacemide

In today's world, Milacemide has become a topic of great relevance and interest. Over time, Milacemide has proven to be a topic that leaves no one indifferent, generating debates, conflicting opinions and endless reflections. The importance of Milacemide lies in its impact on various aspects of daily life, from politics to popular culture. Likewise, Milacemide has been the subject of study and research, giving rise to numerous advances and discoveries that have revolutionized our understanding of the world around us. In this article, we will explore in depth the impact of Milacemide and its influence on different spheres of society.

Milacemide
Skeletal formula of milacemide
Names
IUPAC name
N2-Pentylglycinamide
Systematic IUPAC name
2-(Pentylamino)acetamide
Identifiers
3D model (JSmol)
ChEMBL
ChemSpider
MeSH milacemide
UNII
  • InChI=1S/C7H16N2O/c1-2-3-4-5-9-6-7(8)10/h9H,2-6H2,1H3,(H2,8,10) checkY
    Key: GJNNXIYZWIZFRH-UHFFFAOYSA-N checkY
  • CCCCCNCC(N)=O
Properties
C7H16N2O
Molar mass 144.218 g·mol−1
log P 0.754
Related compounds
Related compounds
 Tricine
Except where otherwise noted, data are given for materials in their standard state (at 25 °C , 100 kPa).

Milacemide (INN) is an MAO-B inhibitor and glycine prodrug. It has been studied for its effects on human memory and as a potential treatment for the symptoms of Alzheimer's disease. Early clinical trials did not show positive results however, and the drug is now abandoned and it is sold as a nonprescription drug or supplement. While milacemide is not an amino-acid, it acts similarly to glycine in the brain.

References

  1. ^ "milacemide - Compound Summary". PubChem Compound. USA: National Center for Biotechnology Information. 8 August 2005. Identifiers and Related Records. Retrieved 9 January 2012.
  2. ^ "International Nonproprietary Names for Pharmaceutical Substances. Supplement to WHO Chronicle, 1983, Vol. 37, No. 6 (December). Recommended International Nonproprietary Names (Rec. INN): List 23" (PDF). World Health Organization. p. 6. Retrieved 8 January 2016.
  3. ^ a b Dysken, MW; Mendels, J; LeWitt, P; Reisberg, B; Pomara, N; Wood, J; Skare, S; Fakouhi, JD; Herting, RL (May 1992). "Milacemide: a placebo-controlled study in senile dementia of the Alzheimer type". Journal of the American Geriatrics Society. 40 (5): 503–6. doi:10.1111/j.1532-5415.1992.tb02019.x. PMID 1634705. S2CID 34816755.
  4. ^ Harris, Carol Turkington ; foreword by Joseph R. (2002). The encyclopedia of the brain and brain disorders (2nd ed.). New York, NY: Facts on File. ISBN 0-8160-4774-X. Archived from the original on 2014-03-03. Retrieved 2017-09-10.{{cite book}}: CS1 maint: multiple names: authors list (link)
  5. ^ Theodore I. Lidsky and Jay S. Schneider Phd, Brain Candy (2001). Brain Candy. New York, United States Of America: Simon & Schuster. ISBN 9780743218436.


Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

Wikious
Boobota
Sagapedia